{"transactions":[{"id":764864,"issuer":{"id":2350,"kind":"organization","name":"Beta Bionics, Inc.","symbol":"BBNX"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-26T22:00:33.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":16965,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."}],"balance_after":29397,"source":{"system":"sec-edgar","filing":"0001810701-26-000003","document":"form4-05262026_060528.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000181070126000003/form4-05262026_060528.xml","form_type":"4"}},{"id":818073,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-03T20:05:04.000Z","date":"2026-04-01","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1094733,"source":{"system":"sec-edgar","filing":"0001193125-26-142100","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000119312526142100/ownership.xml","form_type":"4"}},{"id":939678,"issuer":{"id":2350,"kind":"organization","name":"Beta Bionics, Inc.","symbol":"BBNX"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-15T01:30:10.000Z","date":"2026-01-13","kind":"grant","planned":false,"acquired":true,"shares":3997,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."}],"balance_after":12432,"source":{"system":"sec-edgar","filing":"0001810701-26-000002","document":"form4-01142026_080107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000181070126000002/form4-01142026_080107.xml","form_type":"4"}},{"id":943694,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-08T21:30:11.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":1702,"price":3.364,"value":5725.528,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold to cover taxes upon the vesting of restricted stock units (\"RSUs\") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."}],"balance_after":1096733,"source":{"system":"sec-edgar","filing":"0001193125-26-007751","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000119312526007751/ownership.xml","form_type":"4"}},{"id":984404,"issuer":{"id":2350,"kind":"organization","name":"Beta Bionics, Inc.","symbol":"BBNX"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-02T21:20:06.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":500,"price":29.964,"value":14982.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $29.9640 and the range of prices were between $29.80 and $30.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":8435,"source":{"system":"sec-edgar","filing":"0001810701-25-000007","document":"form4-12022025_041202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000181070125000007/form4-12022025_041202.xml","form_type":"4"}},{"id":984403,"issuer":{"id":2350,"kind":"organization","name":"Beta Bionics, Inc.","symbol":"BBNX"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-02T21:20:06.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":906,"price":29.3269,"value":26570.1714,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $29.3269 and the range of prices were between $28.75 and $29.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":8935,"source":{"system":"sec-edgar","filing":"0001810701-25-000007","document":"form4-12022025_041202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000181070125000007/form4-12022025_041202.xml","form_type":"4"}},{"id":1007495,"issuer":{"id":2350,"kind":"organization","name":"Beta Bionics, Inc.","symbol":"BBNX"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-06T02:45:06.000Z","date":"2025-10-31","kind":"sale","planned":true,"acquired":false,"shares":119,"price":27.4502,"value":3266.5738,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $27.4502 and the range of prices were between $27.32 and $27.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":9841,"source":{"system":"sec-edgar","filing":"0001810701-25-000005","document":"form4-11052025_091101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000181070125000005/form4-11052025_091101.xml","form_type":"4"}},{"id":1007494,"issuer":{"id":2350,"kind":"organization","name":"Beta Bionics, Inc.","symbol":"BBNX"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-06T02:45:06.000Z","date":"2025-10-31","kind":"sale","planned":true,"acquired":false,"shares":1287,"price":26.8588,"value":34567.2756,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $26.8588 and the range of prices were between $26.27 and $27.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":9960,"source":{"system":"sec-edgar","filing":"0001810701-25-000005","document":"form4-11052025_091101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000181070125000005/form4-11052025_091101.xml","form_type":"4"}},{"id":1025874,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-10-03T20:15:09.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":3667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 21, 2024, the Reporting Person was granted a performance stock option (\"PSO\") for an aggregate of up to 11,000 shares of common stock (or 550,000 shares on a pre-split basis) under the Issuer's 2020 Incentive Award Plan (the \"Agreement\").  Under the terms of the Agreement, the underlying PSO shares will vest upon certain milestone events. On October 1, 2025, the Issuer determined that Milestone 2 of the PSO was achieved, resulting in 3,667 PSOs being earned. The earned PSOs will vest on January 31, 2028."}],"balance_after":7333,"derivative":{"exercise_price":303.5,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":3667},"source":{"system":"sec-edgar","filing":"0001193125-25-230193","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000119312525230193/ownership.xml","form_type":"4"}},{"id":1088271,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-07-15T01:27:40.000Z","date":"2025-07-10","kind":"sale","planned":true,"acquired":false,"shares":1565,"price":8.91,"value":13944.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares were sold to cover taxes upon the vesting of restricted stock units (\"RSUs\") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended."}],"balance_after":1098435,"source":{"system":"sec-edgar","filing":"0000950170-25-095682","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000095017025095682/ownership.xml","form_type":"4"}},{"id":1202402,"issuer":{"id":2350,"kind":"organization","name":"Beta Bionics, Inc.","symbol":"BBNX"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-19T00:00:12.000Z","date":"2025-03-15","kind":"grant","planned":false,"acquired":true,"shares":11247,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan."}],"balance_after":11247,"source":{"system":"sec-edgar","filing":"0001415889-25-008536","document":"form4-03182025_080308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000141588925008536/form4-03182025_080308.xml","form_type":"4"}},{"id":1288414,"issuer":{"id":2350,"kind":"organization","name":"Beta Bionics, Inc.","symbol":"BBNX"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-02-04T01:30:19.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":9137,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in 36 equal monthly installments measured from August 15, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock."}],"balance_after":9137,"derivative":{"exercise_price":7.51,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":9137},"source":{"system":"sec-edgar","filing":"0001415889-25-002821","document":"form4-02032025_080215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000141588925002821/form4-02032025_080215.xml","form_type":"4"}},{"id":1305987,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-01-10T21:15:05.000Z","date":"2025-01-08","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in three substantially equal installments occurring on July 1, 2025, January 1, 2026 and July 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":1100000,"source":{"system":"sec-edgar","filing":"0000950170-25-004167","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000095017025004167/ownership.xml","form_type":"4"}},{"id":1336512,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-11T23:54:43.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":183333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 21, 2024, the Reporting Person was granted a performance stock option (\"PSO\") for an aggregate of up to 550,000 shares of common stock under the Issuer's 2020 Incentive Award Plan (the \"Agreement\"). Under the terms of the Agreement, the underlying PSO shares will vest upon certain milestone events.  On December 9, 2024, the Issuer determined that Milestone 1 of the PSO was achieved, resulting in 183,333 PSOs being earned. The earned PSOs will vest on January 31, 2028."}],"balance_after":183333,"derivative":{"exercise_price":6.07,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":183333},"source":{"system":"sec-edgar","filing":"0000950170-24-135537","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000095017024135537/ownership.xml","form_type":"4"}},{"id":1384415,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2024-10-18T20:05:06.000Z","date":"2024-10-16","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\").  Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in three substantially equal installments occurring on April 1, 2025, October 1, 2025 and April 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0000950170-24-115597","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000095017024115597/ownership.xml","form_type":"4"}},{"id":1566520,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2024-03-20T23:20:58.000Z","date":"2024-03-18","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2024."}],"balance_after":500000,"derivative":{"exercise_price":5.77,"expiration_date":"2034-03-17","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-24-034348","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000095017024034348/ownership.xml","form_type":"4"}},{"id":1831221,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2023-07-12T22:36:36.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following June 15, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"This Form 4 amendment is being filed to correct the expiration date of the stock option granted to the Reporting Person."}],"balance_after":150000,"derivative":{"exercise_price":2.99,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-23-032707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000095017023032707/ownership.xml","form_type":"4/A","original_submission_date":"2023-06-26"}},{"id":1844701,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2023-06-26T21:39:26.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following June 15, 2023."}],"balance_after":150000,"derivative":{"exercise_price":2.99,"expiration_date":"2023-06-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-23-029918","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000095017023029918/ownership.xml","form_type":"4"}},{"id":2037442,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2023-02-02T22:09:55.000Z","date":"2023-01-31","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2023."}],"balance_after":250000,"derivative":{"exercise_price":2.85,"expiration_date":"2033-01-30","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-23-003510","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000089924323003510/doc4.xml","form_type":"4"}},{"id":2386675,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2022-02-18T22:12:53.000Z","date":"2022-02-16","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 16, 2022, the Reporting Person was granted an option to purchase 175,000 shares of common stock. The option vests and becomes exercisable as to 58,333 shares underlying the option when the Issuer's market capitalization reaches $250,000,000; (ii) 58,333 shares underlying the option when the Issuer's market capitalization reaches $350,000,000; and (iii) 58,334 shares underlying the option when the Issuer's market capitalization reaches $500,000,000, all subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":175000,"derivative":{"exercise_price":4.21,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000899243-22-007042","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000089924322007042/doc4.xml","form_type":"4"}},{"id":2395764,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2022-02-16T02:31:03.000Z","date":"2022-02-12","kind":"grant","acquired":true,"shares":127400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 12, 2022."}],"balance_after":127400,"derivative":{"exercise_price":4.78,"expiration_date":"2032-02-11","underlying":"Common Stock","underlying_shares":127400},"source":{"system":"sec-edgar","filing":"0000899243-22-006546","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000089924322006546/doc4.xml","form_type":"4"}},{"id":2870332,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2021-02-10T21:05:50.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 8, 2021."}],"balance_after":120000,"derivative":{"exercise_price":10.63,"expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000899243-21-005656","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000089924321005656/doc4.xml","form_type":"4"}},{"id":3165917,"issuer":{"id":46837,"kind":"organization","name":"Lyra Therapeutics, Inc.","symbol":"LYRA"},"owners":[{"id":44481,"kind":"person","name":"Palasis Maria","position":1,"cik":"0001810701","reported_name":"Palasis Maria","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option","published_at":"2020-05-01T22:36:29.000Z","date":"2020-04-30","kind":"grant","acquired":true,"shares":326303,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020."}],"balance_after":326303,"derivative":{"exercise_price":16,"expiration_date":"2030-04-29","underlying":"Common Stock","underlying_shares":326303},"source":{"system":"sec-edgar","filing":"0000899243-20-011749","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810701/000089924320011749/doc4.xml","form_type":"4"}}]}